| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA712: Enzalutamide for treating hormone-sensitive metastatic prostate cancer |
|
Medicine details |
|
| Medicine name | enzalutamide (Xtandi®) |
| Formulation | 40 mg and 80 mg film-coated tablets |
| Reference number | 3137 |
| Indication | Treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT) |
| Company | Astellas Pharma Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 16/04/2021 |
| NICE guidance | TA712: Enzalutamide for treating hormone-sensitive metastatic prostate cancer |